On September 11, 2020 Eli Lilly and Company (NYSE:LLY) reported that it will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 17, 2020 (Press release, Eli Lilly, SEP 11, 2020, View Source [SID1234565007]). Joshua Smiley, senior vice president and Lilly’s chief financial officer, will participate in a virtual fireside chat at 8:40 a.m., Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.

On September 11, 2020 Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, reported that the company will participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference in September (Press release, Ascendis Pharma, SEP 11, 2020, View Source [SID1234565025]). Company executives will provide a business overview and update on the company’s pipeline programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details

Event 18th Annual Morgan Stanley Virtual Global Healthcare Conference
Location Virtual
Date Thursday, September 17, 2020
Time 3:30 p.m. Eastern Time
A live webcast of the presentation will be available in the Investors and News section of the Ascendis Pharma website at www.ascendispharma.com. A webcast replay will also be available on this website shortly after conclusion of the events for 30 days.

On September 11, 2020 Surface Oncology (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that Jeff Goater, its chief executive officer, and Robert Ross, M.D., its chief medical officer, will participate in the upcoming H.C. Wainwright Global Healthcare Conference held on September 14/15, 2020, discussing Surface Oncology’s lead programs, SRF617 (targeting CD39) and SRF388 (targeting IL-27) as well as Surface’s emerging pre-clinical pipeline, highlighted by SRF813 (targeting CD112R, aka PVRIG) (Press release, Surface Oncology, SEP 11, 2020, View Source [SID1234565008]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 11, 2020 Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company dedicated to the development and commercialization of a vaccine candidate to combat the novel coronavirus pandemic (commonly referred to as COVID-19) reported that Alan Joslyn, Ph.D., President and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 22nd Annual Global Investment Conference (the "Conference") (Press release, Oragenics, SEP 11, 2020, View Source [SID1234565026]). The Conference is to be held virtually on September 14–16, 2020, and Dr. Joslyn is scheduled to present on Wednesday, September 16, 2020 at 11:00 AM ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Dr. Joslyn’s presentation will be available through H.C. Wainwright’s virtual conference portal, located here, and the presentation will be archived on the Oragenics website at View Source

In addition, Dr. Joslyn will be available for virtual one-on-one meetings from September 14–16, 2020. To schedule a meeting with Dr. Joslyn, please contact the Conference coordinator at [email protected].

On September 11, 2020 BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, reported that Todd Norbe, President and Chief Executive Officer and John Beaver, Chief Operating Officer and Chief Financial Officer, will be providing an overview of the Company, as well as recent progress and achievements at the H.C. Wainwright 22nd Annual Global Investor Conference on Wednesday, September 16, 2020 at 11:00 am Pacific Time (2:00 pm ET) (Press release, Biolase Technology, SEP 11, 2020, View Source [SID1234565042]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference will feature virtual one-on-one meetings with the BIOLASE’ executives and institutional investors are invited to request meeting times at [email protected] or through their H.C. Wainwright representative. The formal presentation will be webcast live and will be available for replay at View Source or in the investor relations section of BIOLASE’s website at www.biolase.com.